Autopsy report · NCT00062699
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
Cause of deathNo reason given
Life of this trial
- Registered 2 months after it had already started.
- 2,200 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Abbott
- Sponsor type
- Industry
- Conditions
- End-Stage Kidney Disease
- Interventions
- Zemplar (paricalcitol injection); Calcijex
- Participants
- 2,200
- Sites
- 60
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.